Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Soleno Therapeutics Inc’s stock clocked out at $66.94, down -0.42% from its previous closing price of $67.22. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 1.02 million shares were traded. SLNO stock price reached its highest trading level at $68.19 during the session, while it also had its lowest trading level at $65.8456.
Ratios:
To gain a deeper understanding of SLNO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.01 and its Current Ratio is at 15.13. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $123.
On June 23, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $110.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 3574542592 and an Enterprise Value of 3323454976. For the stock, the TTM Price-to-Sale (P/S) ratio is 108.93 while its Price-to-Book (P/B) ratio in mrq is 14.06. Its current Enterprise Value per Revenue stands at 101.769 whereas that against EBITDA is -18.031.
Stock Price History:
The Beta on a monthly basis for SLNO is -2.72, which has changed by 0.34107983 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -16.52%, while the 200-Day Moving Average is calculated to be 4.63%.
Shares Statistics:
It appears that SLNO traded 1.36M shares on average per day over the past three months and 1117810 shares per day over the past ten days. A total of 50.44M shares are outstanding, with a floating share count of 45.97M. Insiders hold about 13.50% of the company’s shares, while institutions hold 96.49% stake in the company. Shares short for SLNO as of 1755216000 were 6307850 with a Short Ratio of 4.64, compared to 1752537600 on 5866108. Therefore, it implies a Short% of Shares Outstanding of 6307850 and a Short% of Float of 13.55.
Earnings Estimates
The current rating of Soleno Therapeutics Inc (SLNO) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.2, with high estimates of $0.62 and low estimates of -$0.41.
Analysts are recommending an EPS of between $0.24 and -$1.69 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is $3.01, with 10.0 analysts recommending between $5.56 and $1.01.
Revenue Estimates
For the next quarter, 10 analysts are estimating revenue of $61.6M. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $40.2M.
Based on 10 analysts’ estimates, the company’s revenue will be $397.47M in the next fiscal year. The high estimate is $551.75M and the low estimate is $252.18M.
